These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 21725702)

  • 1. Apelin, diabetes, and obesity.
    Castan-Laurell I; Dray C; Attané C; Duparc T; Knauf C; Valet P
    Endocrine; 2011 Aug; 40(1):1-9. PubMed ID: 21725702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding role for the apelin/APJ system in physiopathology.
    Carpéné C; Dray C; Attané C; Valet P; Portillo MP; Churruca I; Milagro FI; Castan-Laurell I
    J Physiol Biochem; 2007 Dec; 63(4):359-73. PubMed ID: 18457011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apelin/APJ system as a therapeutic target in diabetes and its complications.
    Hu H; He L; Li L; Chen L
    Mol Genet Metab; 2016 Sep; 119(1-2):20-7. PubMed ID: 27650065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apelin receptors: From signaling to antidiabetic strategy.
    Chaves-Almagro C; Castan-Laurell I; Dray C; Knauf C; Valet P; Masri B
    Eur J Pharmacol; 2015 Sep; 763(Pt B):149-59. PubMed ID: 26007641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis.
    O'Carroll AM; Lolait SJ; Harris LE; Pope GR
    J Endocrinol; 2013 Oct; 219(1):R13-35. PubMed ID: 23943882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothalamic actions of apelin on energy metabolism: new insight on glucose homeostasis and metabolic disorders.
    Knauf C; Drougard A; Fournel A; Duparc T; Valet P
    Horm Metab Res; 2013 Dec; 45(13):928-34. PubMed ID: 23950038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Apelin-APJ System in Diabetes and Obesity.
    Li C; Cheng H; Adhikari BK; Wang S; Yang N; Liu W; Sun J; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():820002. PubMed ID: 35355561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potentials of apelin in obesity-associated diseases.
    Castan-Laurell I; Dray C; Valet P
    Mol Cell Endocrinol; 2021 Jun; 529():111278. PubMed ID: 33838166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apelin targets gut contraction to control glucose metabolism via the brain.
    Fournel A; Drougard A; Duparc T; Marlin A; Brierley SM; Castro J; Le-Gonidec S; Masri B; Colom A; Lucas A; Rousset P; Cenac N; Vergnolle N; Valet P; Cani PD; Knauf C
    Gut; 2017 Feb; 66(2):258-269. PubMed ID: 26565000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New adipokines.
    Fève B; Bastard C; Fellahi S; Bastard JP; Capeau J
    Ann Endocrinol (Paris); 2016 Feb; 77(1):49-56. PubMed ID: 26852251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apelin/APJ system: A novel promising therapy target for pathological angiogenesis.
    Wu L; Chen L; Li L
    Clin Chim Acta; 2017 Mar; 466():78-84. PubMed ID: 28025030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes.
    Kunduzova O; Alet N; Delesque-Touchard N; Millet L; Castan-Laurell I; Muller C; Dray C; Schaeffer P; Herault JP; Savi P; Bono F; Valet P
    FASEB J; 2008 Dec; 22(12):4146-53. PubMed ID: 18708591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of the apelin-APJ axis in vascular formation.
    Kidoya H; Takakura N
    J Biochem; 2012 Aug; 152(2):125-31. PubMed ID: 22745157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
    Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
    Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways.
    Than A; Cheng Y; Foh LC; Leow MK; Lim SC; Chuah YJ; Kang Y; Chen P
    Mol Cell Endocrinol; 2012 Oct; 362(1-2):227-41. PubMed ID: 22842084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.
    Drougard A; Duparc T; Brenachot X; Carneiro L; Gouazé A; Fournel A; Geurts L; Cadoudal T; Prats AC; Pénicaud L; Vieau D; Lesage J; Leloup C; Benani A; Cani PD; Valet P; Knauf C
    Antioxid Redox Signal; 2014 Feb; 20(4):557-73. PubMed ID: 23879244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans.
    Dray C; Debard C; Jager J; Disse E; Daviaud D; Martin P; Attané C; Wanecq E; Guigné C; Bost F; Tanti JF; Laville M; Vidal H; Valet P; Castan-Laurell I
    Am J Physiol Endocrinol Metab; 2010 Jun; 298(6):E1161-9. PubMed ID: 20233941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice.
    Duparc T; Colom A; Cani PD; Massaly N; Rastrelli S; Drougard A; Le Gonidec S; Moulédous L; Frances B; Leclercq I; Llorens-Cortes C; Pospisilik JA; Delzenne NM; Valet P; Castan-Laurell I; Knauf C
    Antioxid Redox Signal; 2011 Sep; 15(6):1477-96. PubMed ID: 21395477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The APJ receptor: a new therapeutic approach in diabetic treatment].
    Masri B; Dray C; Knauf C; Valet P; Castan-Laurell I
    Med Sci (Paris); 2015 Mar; 31(3):275-81. PubMed ID: 25855281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications.
    Ladeiras-Lopes R; Ferreira-Martins J; Leite-Moreira AF
    Arq Bras Cardiol; 2008 May; 90(5):343-9. PubMed ID: 18516406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.